source
- Minghui licenses sub-q TED drug to Japan's ASKA in up to $440 million dealMinghui Pharmaceutical of China has signed a licensing agreement with Japan's ASKA Pharmaceutical, granting exclusive rights to develop and sell its late‑stage thyroid eye disease (TED) candidate i…
- Blackstone Life Sciences and Boston Scientific launch $455 million partnership to develop next-generation heart pumpBlackstone Life Sciences has entered a collaboration with Boston Scientific, committing $455 million to co‑fund development of a next‑generation miniature heart pump system. The device, called the…